Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity
Science Signaling · 17.11.2026 · 19 (964)
DOI: 10.1126/scisignal.aef1375 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, erschienen am 17.11.2026. Verfasst von Kristen N. Gilley und 10 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Institutes of Health, North Carolina Biotechnology Center, Lung Cancer Research Foundation.
Abstract (Originalsprache)
Immune checkpoint inhibition (ICI) has improved outcomes for some patients with advanced malignancies, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Here, we explored the link between alcohol use and ICI efficacy in mouse models of lung and bladder cancers and performed a retrospective assessment of a cohort of patients with cancer receiving ICI therapy. In both mouse models, a regimen of moderate-to-heavy ethanol intake reduced ICI efficacy by ∼50% and increased tumor recurrence. In patients with lung cancer, regular alcohol use was associated with reduced survival benefit from ICI. Effects were less definitive in patients with bladder cancer, melanoma, and head and neck cancer, in whom alcohol use reporting was too limited. In mice bearing MB49 bladder tumors, ethanol intake reduced the number of tumor-infiltrated T cells favoring T helper 17 cell (T H 17 cell) over T H 1 cell phenotypes in tumor-associated CD4 + T cells. It also reduced the number of tissue-resident memory T cells, increased the proportion of T cells expressing the alternative immune checkpoint receptor TIGIT, and induced SREBP-mediated lipid signaling in tumor-associated T cells. Blocking TIGIT with antibodies or, to a lesser extent, inhibiting SREBP signaling with betulin improved the efficacy of PD1 receptor blockade. The findings suggest that regular alcohol use negatively affects ICI efficacy, which may be counteracted by cotargeting TIGIT. Future incorporation of patients’ alcohol use in cancer databases will help define its effect on the outcome of various therapies in multiple cancers.
Förderung
- National Institutes of Health
- North Carolina Biotechnology Center
- Lung Cancer Research Foundation
- Free To Breathe
- School of Medicine, University of North Carolina at Chapel Hill
- National Institute of Health
Zitieren
APA
Gilley, K. N., Garness, J., Khan, A., Materia, B. R., Carpenter, B., Shabrang, M., Beckabir, W., Woodcock, M. G., Pecot, C. V., Vincent, B. G., & Coleman, L. G. (2026). Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity. Science Signaling, 19(964). https://doi.org/10.1126/scisignal.aef1375
Vancouver
Gilley KN, Garness J, Khan A, Materia BR, Carpenter B, Shabrang M, et al. Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity. Science Signaling. 2026;19(964). doi:10.1126/scisignal.aef1375
BibTeX
@article{Gilley2026,
author = {Gilley, Kristen N. and Garness, Jason and Khan, Ali and Materia, Baylee R. and Carpenter, Brandon and Shabrang, Mitra and Beckabir, Wolfgang and Woodcock, Mark G. and Pecot, Chad V. and Vincent, Benjamin G. and Coleman, Leon G.},
title = {Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity},
journal = {Science Signaling},
year = {2026},
volume = {19},
number = {964},
doi = {10.1126/scisignal.aef1375}
}
EUVIMED